Tesaro brings to GSK a marketed product for ovarian cancer, Zejula, which belongs to a promising new class of medicines.  Photograph: Toby Melville/Reuters

GlaxoSmithKline has agreed to buy US cancer specialist Tesaro for $5.1 billion (€4.5 billion), marking a major biotech investment by chief executive E(...)